Importance of Relative Dose Intensity in Chemotherapy for Diffuse Large B-Cell Lymphoma
Open Access
- 1 January 2011
- journal article
- review article
- Published by Japanese Society for Lymphoreticular Tissue Research in Journal of Clinical and Experimental Hematopathology
- Vol. 51 (1) , 1-5
Abstract
CHOP therapy combined with rituximab (R-CHOP) is currently a standard chemotherapy for diffuse large B-cell lymphoma (DLBCL). However, relapse is detected despite R-CHOP in approximately 30% of patients. Treatment results should be further improved. Previously, second- and third-generation therapies such as MACOP-B, m-BACOD, and ProMACE-CytaBOM were performed to improve the results of DLBCL treatment. However, dose intensity (DI) enhancement increased treatment-associated toxicity, and the treatment results did not improve. Recently, the entity of the relative dose intensity (RDI) was proposed as an index of the intensity of chemotherapy. In this method, the ratio of actual DI to the DI designed per specific period is numerically evaluated. The purpose of calculating the RDI is to achieve chemotherapy as scheduled while maintaining the DI, and not to improve the DI. Previous studies reported that the maintenance of the RDI during CHOP therapy improved the treatment results. In this paper, we review DI and RDI in studies of DLBCL, and revisit the significance of these indicators. [J Clin Exp Hematopathol 51(1) : 1-5, 2011]Keywords
This publication has 13 references indexed in Scilit:
- Association of reduced relative dose intensity and survival in lymphoma patients receiving CHOP-21 chemotherapyAnnals of Hematology, 2008
- 2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice GuidelineJournal of Clinical Oncology, 2006
- CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) GroupThe Lancet Oncology, 2006
- Incidence and Predictors of Low Chemotherapy Dose-Intensity in Aggressive Non-Hodgkin's Lymphoma: A Nationwide StudyJournal of Clinical Oncology, 2004
- Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHLBlood, 2004
- Shortened First-Line High-Dose Chemotherapy for Patients With Poor-Prognosis Aggressive LymphomaJournal of Clinical Oncology, 2002
- CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell LymphomaNew England Journal of Medicine, 2002
- Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: Application to LNH-87 protocolAnnals of Oncology, 1993
- Comparison of a Second-Generation Combination Chemotherapeutic Regimen (m-BACOD) with a Standard Regimen (CHOP) for Advanced Diffuse Non-Hodgkin's LymphomaNew England Journal of Medicine, 1992
- Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis.Journal of Clinical Oncology, 1990